COVID-19 & Psoriasis Resource Center

To assist dermatologists and the patients they serve, the IPC is collecting information from around the world on coronavirus and psoriasis. If you have a resource on COVID-19 and psoriasis to add, please submit it to IPC.

Latest news on COVID-19 & Psoriasis

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.

February 08, 2021

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

February 02, 2021

Commentary: NPF COVID-19 Task Force Guidance Statements

January 06, 2021

IPC Statement on SARS-CoV-2 Vaccines and Psoriasis

December 02, 2020

IPC Statement on COVID-19 & PsoriasisIPC's statement provides general guidance to physicians treating psoriasis patients based on the current understanding of the impact of COVID-19 and psoriasis.

Expert Opinions

Hear from world psoriasis experts their take on the most current publications on COVID-19.

Stories from the Field View videos and read interviews from some of IPC's experts regarding the impact on psoriasis care during the COVID-19 pandemic.

Treatment GuidelinesView recommendations from professional and patient societies around the globe that have provided additional information regarding treating patients with psoriasis during the COVID-19 pandemic.

PsoProtect Registry

Help us learn more about the impact on psoriasis and COVID-19 by participating in this global registry. You can submit a case on-line.

Key Publications Review articles on COVID-19 selected by IPC's Chief Medical Officer.

IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT

The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.

READ STATEMENTS

this weeks' publications on covid-19 & psoriasis

Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation
Rapid online surveys may help illuminate patient perspectives about the SARS-COV-2 virus and the COVID-19 pandemic, allowing clinicians to address these concerns.(1) To understand patient perspectives during the early phases of the COVID-19 pandemic, the National Psoriasis Foundation (NPF) conducted a two-wave survey of a random stratified sample of individuals 18 years of age or older with psoriatic disease in the United States who recently contacted the NPF.

A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comte, France
No abstract

Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19
No abstract

Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China
No abstract

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments
CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.

VIEW ALL ON PUBMED

resources from our industry partners

AbbVie
Amgen
Novartis
UCB